A Study of HS-20094 Versus Dulaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabete

ClinicalTrials5 Sept 2025·Phase 3● 4/10i

A Study of HS-20094 Versus Dulaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabete

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3 trial tests HS-20094, a once-weekly GLP-1 receptor agonist, versus dulaglutide in 546 adults with type 2 diabetes inadequately controlled on metformin alone or with SGLT2 inhibitors. Open-label comparison running 52 weeks with HbA1c reduction as primary endpoint, completion expected March 2027. Jiangsu Hansoh enters the competitive once-weekly GLP-1 space dominated by Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, targeting the large metformin-failure population. Direct head-to-head with dulaglutide positions this Chinese biosimilar for potential market share in Asia-Pacific regions.

Strategic signal

Hansoh's head-to-head design against dulaglutide signals preparation for biosimilar-level pricing rather than premium positioning against market leaders Ozempic and Mounjaro. The 52-week duration and metformin-failure population mirror registration strategies used by established GLP-1s, suggesting regulatory filing intent in China and potentially other Asian markets. This follows the SGLT2 inhibitor playbook where Chinese companies captured significant domestic market share through competitive pricing of clinically equivalent products.

GLP-1Type 2 diabetesDrug comparisonsJiangsu Hansoh Pharmaceutical

Original Abstract

The study is being conducted to evaluate the efficacy and safety of HS-20094 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Dulaglutide QW for 44 weeks and 52 weeks. | Condition(s): Type 2 Diabetes | Primary endpoint(s): Change in HbA1c | Enrollment: 546 (estimated) | Phase: Phase 3 | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Expected completion: 2027-03-30 | Status: Not Yet Recruiting | Last update: 2025-09-05

View original source ↗

Related signals

FDA1 Apr 2026·New Drug Approval (NDA/BLA)● 10/10iHigh impact

FDA Approves Foundayo (Orforglipron) — New Drug Approval (NDA/BLA)

FDA approved orforglipron (Foundayo, Eli Lilly) for type 2 diabetes -- a once-daily oral small-molecule GLP-1 receptor agonist. Orforglipron is the first non-peptide oral GLP-1 approved in the US; oral semaglutide (Rybelsus, Novo Nordisk) has been approved for T2D since 2019 and expanded to obesity in January 2026. Unlike Rybelsus, orforglipron requires no fasting or water volume restrictions before dosing.

GLP-1Type 2 diabetesPricing/accessEli Lilly Novo Nordisk

ClinicalTrials19 Mar 2026·Phase 3● 9/10iHigh impact

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Phase 3 SURMOUNT-1 tests once-weekly tirzepatide at three doses versus placebo in adults without type 2 diabetes who have obesity or are overweight with comorbidities. The randomized, double-blind trial targets 2,539 participants with primary efficacy assessment at 72 weeks. This represents tirzepatide's pivotal obesity trial against placebo, potentially supporting Eli Lilly's bid to compete directly with Wegovy in the non-diabetic obesity market. A prediabetes subgroup continues long-term to assess diabetes prevention.

Weight lossGLP-1Eli Lilly

ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impactPick of the week

The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis

Phase 3 trial evaluates semaglutide versus placebo in adults with non-cirrhotic NASH, measuring steatohepatitis resolution, fibrosis improvement, and cirrhosis-free survival over approximately 5 years. The study enrolled 1,205 adults and is active but not recruiting, with completion expected in 2029. This represents Novo Nordisk's push into NASH, a major unmet need with no approved GLP-1 therapies despite strong preclinical rationale. The trial's dual primary endpoints and 5-year duration suggest preparation for a pivotal regulatory filing in this large addressable market.

GLP-1Liver/NASHNovo Nordisk

ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Phase 3 trial evaluating retatrutide for chronic low back pain in people with obesity or overweight, targeting dual primary endpoints of pain intensity reduction and weight loss. 586-person placebo-controlled study expected to complete September 2027, investigating a novel indication beyond traditional metabolic endpoints. Eli Lilly is exploring pain management as a potential expansion for their triple agonist, representing the first major trial of a GLP-1-based therapy specifically for chronic pain conditions.

GLP-1Weight lossOtherEli Lilly